Literature DB >> 7558420

DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.

K J Mellish1, C F Barnard, B A Murrer, L R Kelland.   

Abstract

We have investigated the comparative initial DNA binding properties of 7 platinum-based anticancer drugs: 5 cis-oriented compounds, cisplatin, tetraplatin (Ormaplatin), JM118 [cis ammine dichloro (cyclohexylamine) platinum (II)], JM216 [bisacetato cis ammine dichloro (cyclohexylamine) platinum (IV)] and JM149 [cis ammine dichloro (cyclohexylamine) trans dihydroxo platinum (IV)], and 2 trans-oriented compounds, transplatin and JM335 [trans ammine dichloro (cyclohexylamine) dihydroxo platinum (IV)] in SKOV-3 and CHI human ovarian carcinoma cells. Unlike transplatin, the trans complex JM335 was comparably cytotoxic to its cis isomer JM149 and cisplatin. No significant correlation was observed between levels of total platinum bound to DNA after exposure to the 7 drugs and cytotoxicity in either cell line. Using a competitive enzyme-linked immunoabsorbent assay, DNA extracted from CH1 cells exposed to the 5 cis platinum drugs was recognized by the monoclonal antibody ICR4 (raised against DNA platinated by cisplatin) in the order JM118 > cisplatin > JM216 > tetraplatin > JM149; a strong positive correlation which just attained statistical significance was observed between recognition by ICR4 and cytotoxicity. In contrast, DNA extracted from CH1 cells exposed to the trans platinum drugs transplatin and JM335 was no more immunoreactive than control DNA. Using alkaline elution, interstrand cross-link levels after exposure to drug did not correlate with cytotoxicity in either cell line. The 5 cis drugs formed interstrand cross-links in both cell lines, whereas transplatin formed very low levels in SKOV-3 and undetectable levels in CH1. JM335 was efficient at forming interstrand cross-links in SKOV-3 but, notably, none were observed in CH1. In contrast, in the CH1 cells, single-strand breaks were observed with JM335 (but not with any other drug). The novel trans complex JM335 was unique, among the platinum drugs studied, in its ability to form both DNA interstrand cross-links and single strand breaks (DNA lesion formation being cell line dependent), a property which may account for its cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558420     DOI: 10.1002/ijc.2910620612

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Activity and DNA binding of new organoamidoplatinum (II) complexes.

Authors:  T Talarico; D R Phillips; G B Deacon; S Rainone; L K Webster
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Effect of geometric isomerism in dinuclear platinum antitumour complexes on the rate of formation and structure of intrastrand adducts with oligonucleotides.

Authors:  K J Mellish; Y Qu; N Scarsdale; N Farrell
Journal:  Nucleic Acids Res       Date:  1997-03-15       Impact factor: 16.971

4.  A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.

Authors:  Jeremy Cetnar; George Wilding; Douglas McNeel; Noelle K LoConte; Thomas A McFarland; Jens Eickhoff; Glenn Liu
Journal:  Urol Oncol       Date:  2011-04-11       Impact factor: 3.498

5.  Superhelical torsion controls DNA interstrand cross-linking by antitumor cis- diamminedichloroplatinum(II).

Authors:  O Vrána; V Boudný; V Brabec
Journal:  Nucleic Acids Res       Date:  1996-10-15       Impact factor: 16.971

6.  The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.

Authors:  Veronika Kvardova; Roman Hrstka; Dawid Walerych; Petr Muller; Eva Matoulkova; Veronika Hruskova; Dagmar Stelclova; Petr Sova; Borivoj Vojtesek
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

Review 7.  Satraplatin: leading the new generation of oral platinum agents.

Authors:  Ashish Bhargava; Ulka N Vaishampayan
Journal:  Expert Opin Investig Drugs       Date:  2009-11       Impact factor: 6.206

8.  Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Authors:  William D Figg; Cindy H Chau; Ravi A Madan; James L Gulley; Rui Gao; Tristan M Sissung; Shawn Spencer; Melony Beatson; Jeanny Aragon-Ching; Seth M Steinberg; William L Dahut
Journal:  Clin Genitourin Cancer       Date:  2013-05-17       Impact factor: 2.872

Review 9.  Platinum Complexes in Colorectal Cancer and Other Solid Tumors.

Authors:  Beate Köberle; Sarah Schoch
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

10.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.

Authors:  J Holford; S Y Sharp; B A Murrer; M Abrams; L R Kelland
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.